Silvia Nardella

As a Director of a Marketing Consultancy, I offer a wide range of solutions for managers based on 31 years of experience, a continuous development of skills, and the support of a multidisciplinary team. • MKT consultant in Strategy & Life Cycle Management. Launch readiness, Awareness campaigns, Marketing Plans, Portfolio Management Patient Journey and Patient Flow development. Stakeholders mapping • Digital Strategy. Immersive experiences development (virtual and augmented reality. Gamification) • VoC Programs: Cx (Customer/patient experience), Bx (Brand experience) & Ex( (Employee experience) • Scientific & Corporate events • Business Coaching & Mentoring Training & Development: • Academic Coordinator Postgraduate: High Cost Medicines Strategic Management in the Pharmaceutical Industry (Belgrano University). • Academic Coordinator of the 1st Digital Program for Pharmaceutical Managers (Belgrano University) and In-Company Digital Programs for Latam • UCES University: Professor , Pharmaceutical MKT Program • UB. University: Professor, Pharmaceutical MKT Program • Patient Journey & Digital Patient Journey Workshop (inCompany) • Patient Experience in Health Institutions • Marketing Plan Workshop

Portfolio: Copaxone (Glatiramer Ac.),Trenazin (Tetrabenazine), future launches. Copaxone is a leading Brand in the global Multiple Sclerosis market. #1brand of Teva/Ivax at global & local level; it represents in Argentina 20% of the company sales. Reporting Positions: 7 Rep´s Current responsibilities: • MKT Strategy&Tactics. • Sales and P&L responsibility. • Sales team leader: training, deployment, SFE and coaching • Participation in new strategic plans of the Company • Development and launch of new products&segments

• Private consultancy for 2 labs in Pain&Dyslipidemia segments

ENBREL(etanercept), the leading Biologic for Rheumatoid Arthritis&Psoriasis, is the 1st brand for Pfizer Argentina, representing 30% of the country sales and is also the 1st brand of the Pharmaceutical Argentinean Market. Reporting Position: 1CBL Junior • Enbrel Leader for Argentina, Uruguay&Paraguay, reporting to the LA Regional Team, with P&L responsibility. • Redefinition of the defensive strategy against Biosimilars. 2013 Plan Implementation. 2014 Strategic Plan development. Renewal of the Patient Program. • Results in 2013 reached 112% over budget.

Portfolio: 9 brands - 100% Budget accomplishment in 2012. Core brands: Lipitor (Atorvastatin), Aldactone/Inspra (Spironolactone/Eplerenone), Amloc/Norvasc (Amlodipine), Reporting Positions: 4District Managers, 47REPs , 2Brand Managers, 1KAM, Assistant . •The team was redeployed with 15 new hires (Reps&DM), increasing by 40% the target coverage. Improvement of Field Force Effectiveness follow up&metrics. Incentives&compensation management. •The Cardiovascular strategic portfolio approach was reoriented due to Lipitor´s take-back, and the brand reached 102%of budget in its 1st year at Pfizer. •I was member of the Lipitor Latin America Team and also actively participated in Apixaban(Anticoagulant) pre-marketing in partnership with BMS Laboratory. •I led 2 Primary Care projects; HR & Digital Strategy.

Brand: Champix (Varenicline) Reporting Positions: 5REPs, 1KAM, 1assistant. •I was responsible for a high-performing team of 5 Reps, with a different business model approach that consolidated the work with KOL´s/Societies/Payers/Government/Companies and NGO´s. •I was a member of the CHAMPIX LA Regional Team participating in the Strategic Plan and Campaign developments. •The Argentine Team, in partnership with LALCEC(NGO) won twice the Pfizer Foundation Microgrant, and once the Center of Expertise (Emerging Markets Projects Award).

Portfolio: 5 brands, Ibupirac (Ibuprofen), Lyrica (Pregabalin), Neurontin (Gabapentin), Dolten(Ketorolac), Celebrex (Celecoxib). Results 2009:103% Budget accomplishment, 24%growth. Reporting positions: 3Brand Managers. •I focused on team development through coaching & training •We implemented significant changes in Lyrica´s market definition, price strategy and promotion by target. Those changes assured a better competition against new generics and a sustainable growth. •Ibupirac Soft Gel capsules was successfully launched

I led IBUPIRAC (Ibuprofen) for 9 years, coordinating a cross-functional team. During this period Ibupirac was the 1st brand of Pharmacia/Pfizer , representing approx. 30% of the company revenues The brand became the #1 Retail selling brand in the Argentine Pharma Market since 2003 (IMS $LC)), and increased revenues from $30M to $105M (LC), consistently reaching business objectives. I occupied different positions over the years of IBUPIRAC Management, interacting with different sales teams, according to changes in company structure. Main Achievements: •Ibupirac´s integration to Pfizer´s culture, by reorganizing and successfully merging both companies’ abilities (Pharmacia acquisition 2003) •Long term life-cycle strategy management. Development and launch of new brands and presentations to target different segments (Flex/600/Grip/800/ Suspensión 4%/Gotas/Junior/ Fem/400 Soft Gel capsule). •Successful Ibupirac 400mg switch to OTC in 2005: pre&post switch strategy design and implementation (physicians, pharmacies&consumers). The switch positively improved brand image and impacted revenues (44%growth in values, in the first year) •Promotional ATL&BTL campaigns development, according to each target, Repositioned and modernized brand image. Renewed packaging of the total line. I boosted the pediatric sales by structuring a new and clear positioning of its 4 line extensions. •Permanent adaptation of the commercial strategy to increase sales&ROI: 2001 crisis, generic law & OTC competition launches 2002, switch pricing strategy, opening of new distribution channels, Soft gel launch.

Porfolio: 9 brands (Rheumatology&Osteoporosis). Responsible for 5 launches and promotional campaigns; Strong relationship with Medical Societies.

Area organization, communication strategy and promotional campaigns for Business Lines: Oncology, Neuro/Psychiatry, Gynecology, Rheumatology. Coordination of internal&external stakeholders. Active participation in new products launches.

Primary&Secondary Market Research and Data Analysis (IMS/INTE; Close Up).